Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lysine-3,4-methylenedioxymethamphetamine
- Development stage
- Phase 1
- Lead developer
- University Hospital Basel
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lysine-3,4-methylenedioxymethamphetamine (Lys-MDMA) is a small molecule prodrug of MDMA (3,4-methylenedioxymethamphetamine) developed by the University Hospital Basel and licensed to Mind Medicine. It was designed as a lysine-conjugated amphetamine intended to slowly release active MDMA upon absorption, thereby potentially enhancing tolerability, reducing abuse potential, and mitigating rapid physiological changes (such as blood pressure spikes) at the onset of drug action. While MDMA is a potent releaser of serotonin, norepinephrine, and dopamine being investigated for the treatment of post-traumatic stress disorder (PTSD), Lys-MDMA was found to be pharmacologically inactive in a Phase 1 crossover trial in healthy volunteers, as it failed to produce detectable MDMA plasma concentrations or clinical effects.
- Other names
- Lysine-MDMALysine-conjugated MDMA
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on lysine-3,4-methylenedioxymethamphetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lysine-3,4-methylenedioxymethamphetamine.